Key result
, no (). No new claims.
Why the study?
Empagliflozin demonstrates beneficial effects in CVD, but its protective role and influence on microRNAs in hypoxic cardiomyocytes require evaluation.
Does empagliflozin modulate microRNA expression in human primary cardiomyocytes under CoCl2-induced hypoxia?
Does empagliflozin modulate microRNA expression in human primary cardiomyocytes under CoCl2-induced hypoxia?
Empagliflozin demonstrates direct cardioprotective effects in hypoxic cardiomyocytes by upregulating miR-214-3p, highlighting its potential role as an epigenetic modulator.
Should not yet change clinical practice; leaves open empagliflozin's potential as epigenetic modulator in hypoxic cardiomyocytes.
Cardiovascular diseases (CVD) remain the leading cause of premature death worldwide, with a steadily rising incidence. Ischemia, characterized by insufficient blood flow and subsequent tissue hypoxia, contributes significantly to cellular damage, dysfunction, as well as epigenetic alterations in CVD. Hypoxia-induced epigenetic changes have been associated with fibrosis, inflammation, metabolic dysregulation, and altered programmed cell death in cardiac tissue. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor primarily prescribed for type 2 diabetes, has also demonstrated beneficial effects in patients with CVD. The present study aimed to evaluate the protective role of Empagliflozin in primary human cardiomyocytes under chemically induced hypoxia, with a focus on its influence on specific microRNAs. Cardioprotective effects were analyzed through the expression of miR-214-3p, miR-22-5p, miR-103-5p, and miR-145-5p, along with protein levels of GAPDH and HIF1α. After 24 hours of Empagliflozin treatment, a significant upregulation of the cardioprotective miR-214-3p (p < 0.05) was observed. These findings demonstrate a direct cardioprotective effect of Empagliflozin in cobalt-treated cardiomyocytes and suggest its potential role as an epigenetic modulator in the pathogenesis of CVD.
No takes yet. Share an insight, caveat, or question.
Samec et al. (2026) studied this question. Empagliflozin significantly upregulated the cardioprotective microRNA miR-214-3p (p < 0.05) in human primary cardiomyocytes exposed to chemically induced hypoxia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Molecular Mechanisms of Cardiac RemodelingMore from International Journal of Cardiology Cardiovascular Risk and Prevention